Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib + MEC in R/R AML and High Risk MDS
NCT03735446Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 42 days. Started Jan 2019; status: terminated.
02
Drugs
prexasertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03735446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735446.